HUE049201T2 - Eljárás glikoprotein glikántartalmának befolyásolására - Google Patents
Eljárás glikoprotein glikántartalmának befolyásolásáraInfo
- Publication number
- HUE049201T2 HUE049201T2 HUE15816598A HUE15816598A HUE049201T2 HU E049201 T2 HUE049201 T2 HU E049201T2 HU E15816598 A HUE15816598 A HU E15816598A HU E15816598 A HUE15816598 A HU E15816598A HU E049201 T2 HUE049201 T2 HU E049201T2
- Authority
- HU
- Hungary
- Prior art keywords
- glycoprotein
- influencing
- glycan content
- glycan
- content
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C07K16/242—Lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462085759P | 2014-12-01 | 2014-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE049201T2 true HUE049201T2 (hu) | 2020-09-28 |
Family
ID=55024253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15816598A HUE049201T2 (hu) | 2014-12-01 | 2015-12-01 | Eljárás glikoprotein glikántartalmának befolyásolására |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10167492B2 (esLanguage) |
| EP (2) | EP3227454B1 (esLanguage) |
| JP (4) | JP6698681B2 (esLanguage) |
| KR (1) | KR102623965B1 (esLanguage) |
| CN (1) | CN107109455B (esLanguage) |
| AU (5) | AU2015355087C1 (esLanguage) |
| CA (1) | CA2969225C (esLanguage) |
| CL (1) | CL2017001369A1 (esLanguage) |
| CY (1) | CY1123247T1 (esLanguage) |
| DK (1) | DK3227454T3 (esLanguage) |
| EA (2) | EA202091598A3 (esLanguage) |
| ES (1) | ES2784503T3 (esLanguage) |
| HU (1) | HUE049201T2 (esLanguage) |
| IL (2) | IL276165B (esLanguage) |
| LT (1) | LT3227454T (esLanguage) |
| MX (1) | MX385409B (esLanguage) |
| PL (1) | PL3227454T3 (esLanguage) |
| PT (1) | PT3227454T (esLanguage) |
| SG (2) | SG11201704351WA (esLanguage) |
| SI (1) | SI3227454T1 (esLanguage) |
| WO (1) | WO2016089919A1 (esLanguage) |
| ZA (2) | ZA201703729B (esLanguage) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102623965B1 (ko) | 2014-12-01 | 2024-01-11 | 암젠 인크 | 당단백질의 글리칸 함량 수준을 조작하는 방법 |
| US11719704B2 (en) | 2015-12-30 | 2023-08-08 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
| WO2018170099A1 (en) | 2017-03-14 | 2018-09-20 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| JP6943972B2 (ja) * | 2017-03-31 | 2021-10-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 灌流培地 |
| WO2019105444A1 (zh) * | 2017-11-30 | 2019-06-06 | 正大天晴药业集团南京顺欣制药有限公司 | 蛋白质的生产方法 |
| SG11202009216YA (en) | 2018-03-26 | 2020-10-29 | Amgen Inc | Total afucosylated glycoforms of antibodies produced in cell culture |
| CA3099917A1 (en) * | 2018-05-24 | 2019-11-28 | Ares Trading S.A. | Method for controlling the afucosylation level of a glycoprotein composition |
| MA52783A (fr) | 2018-06-05 | 2021-04-14 | Amgen Inc | Modulation de la phagocytose cellulaire dépendant de l'anticorps |
| MA53603A (fr) | 2018-09-11 | 2021-07-21 | Amgen Inc | Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| US11634499B2 (en) | 2018-11-13 | 2023-04-25 | Janssen Biotech, Inc. | Control of trace metals during production of anti-CD38 antibodies |
| BR112021012973A2 (pt) | 2018-12-31 | 2021-09-14 | Momenta Pharmaceuticals, Inc. | Métodos de produção de ustequinumabe |
| AU2020216368B2 (en) * | 2019-01-30 | 2025-04-24 | Amgen Inc. | Aflibercept attributes and methods of characterizing and modifying thereof |
| BR112021022202A2 (pt) | 2019-05-06 | 2021-12-28 | Amgen Inc | Modulação de funções efetoras de anticorpo |
| JP2020188737A (ja) * | 2019-05-23 | 2020-11-26 | 東ソー株式会社 | 抗体依存性細胞傷害活性が向上した抗体の製造方法 |
| AU2020355251A1 (en) | 2019-09-26 | 2022-04-21 | Amgen Inc. | Methods of producing antibody compositions |
| KR20220100934A (ko) | 2019-11-15 | 2022-07-18 | 론자 리미티드 | 접종물을 제조하기 위한 공정 및 시스템 |
| WO2022026451A1 (en) * | 2020-07-30 | 2022-02-03 | Amgen Inc. | Cell culture media and methods of making and using the same |
| CN116391043A (zh) * | 2020-08-14 | 2023-07-04 | 百时美施贵宝公司 | 蛋白质的制造方法 |
| EP4229080A1 (en) | 2020-10-15 | 2023-08-23 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| CA3222409A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| CA3251442A1 (en) * | 2022-02-25 | 2023-08-31 | Kashiv Biosciences, Llc | METHOD FOR IMPROVING POLYPEPTIDE EXPRESSION IN A MAMMALIAN CELL CULTURE |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025036924A1 (en) * | 2023-08-16 | 2025-02-20 | Glaxosmithkline Intellectual Property Limited | Method of controlling antibody glycosylation profile |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| AU588819B2 (en) | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| EP0417563B1 (de) | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| US6204363B1 (en) | 1989-10-16 | 2001-03-20 | Amgen Inc. | Stem cell factor |
| US5149792A (en) | 1989-12-19 | 1992-09-22 | Amgen Inc. | Platelet-derived growth factor B chain analogs |
| US5272064A (en) | 1989-12-19 | 1993-12-21 | Amgen Inc. | DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof |
| US5096816A (en) | 1990-06-05 | 1992-03-17 | Cetus Corporation | In vitro management of ammonia's effect on glycosylation of cell products through pH control |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| ES2198414T3 (es) | 1992-10-23 | 2004-02-01 | Immunex Corporation | Procedimientos para preparar proteinas oligomericas solubles. |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| US5981713A (en) | 1994-10-13 | 1999-11-09 | Applied Research Systems Ars Holding N.V. | Antibodies to intereleukin-1 antagonists |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| EP1666591B1 (en) | 1995-06-29 | 2011-03-23 | Immunex Corporation | Cytokine that induces apoptosis |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| JP2001120262A (ja) | 1999-10-26 | 2001-05-08 | Welfide Corp | 生理活性物質の産生増強方法 |
| AU1920301A (en) | 1999-11-17 | 2001-05-30 | Immunex Corporation | Receptor activator of nf-kappa b |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| TWI314933B (en) | 2000-05-26 | 2009-09-21 | Bristol Myers Squibb Compan | Soluble ctla4 mutant molecules and uses thereof |
| JPWO2003085119A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 |
| DE10312765A1 (de) | 2003-03-21 | 2004-09-30 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| US7300773B2 (en) * | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| US8053238B2 (en) | 2005-10-31 | 2011-11-08 | Unhwa Corporation | Isolated population of plant single cells and method of preparing the same |
| US20070231895A1 (en) | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
| EP2495308A1 (en) | 2005-12-08 | 2012-09-05 | Amgen Inc. | Improved production of glycoproteins using manganese |
| WO2007081031A1 (ja) * | 2006-01-16 | 2007-07-19 | Hokkaido University | 糖転移酵素阻害剤 |
| US20100166741A1 (en) * | 2006-07-13 | 2010-07-01 | Genentech , Inc. | Altered br-3 binding polypeptides |
| EP2495307B9 (en) | 2006-07-13 | 2018-05-02 | Wyeth LLC | Production of coagulation factor IX with improved glycosylation pattern |
| FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
| EP2395077A1 (en) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
| SI2115126T1 (sl) | 2007-03-02 | 2015-06-30 | Wyeth Llc | Uporaba bakra in glutamata v celični kulturi za proizvodnjo polipeptidov |
| EP2137320A4 (en) * | 2007-03-30 | 2010-06-16 | Centocor Ortho Biotech Inc | HIGH-EXPRESSION CLONES OF MAMMALIAN CELLS WITH A FLUORESCENT PROTEIN A OR G |
| ES2389618T3 (es) | 2007-04-16 | 2012-10-29 | Momenta Pharmaceuticals, Inc. | Productos de glucoproteínas definidas y métodos relacionados |
| US20100221823A1 (en) | 2007-06-11 | 2010-09-02 | Amgen Inc. | Method for culturing mammalian cells to improve recombinant protein production |
| DK2173861T4 (en) | 2007-06-15 | 2017-05-15 | Amgen Inc | Methods for treating a cell culture medium for use in a bioreactor |
| US20120277165A1 (en) | 2009-06-05 | 2012-11-01 | Collins Brian E | Methods of modulating fucosylation of glycoproteins |
| EP2629798A4 (en) | 2010-10-20 | 2014-05-28 | Morphotek Inc | GLYCOFORMS OF ANTI-RECEPTOR ANTIBODY-ALPHA FOLATE (ANTI-FRA) |
| AU2012220861A1 (en) | 2011-02-23 | 2013-09-05 | Amgen Inc. | Cell culture media for UVC exposure and methods related thereto |
| CN109797138A (zh) * | 2011-03-06 | 2019-05-24 | 默克雪兰诺有限公司 | 低岩藻糖细胞系及其应用 |
| WO2012145682A1 (en) | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US11292829B2 (en) | 2011-07-01 | 2022-04-05 | Amgen Inc. | Mammalian cell culture |
| AR087433A1 (es) * | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| BR112014008303A2 (pt) | 2011-09-16 | 2017-04-11 | Amgen Inc | alimentação contínua controlada pré-programada sem feedback de culturas celulares |
| EA034347B1 (ru) | 2011-10-26 | 2020-01-30 | Амген Инк. | Способ инактивации вирусов при получении антител |
| US20150119558A1 (en) * | 2012-01-20 | 2015-04-30 | Agency For Science, Technology And Research | Cho-gmt recombinant protein expression |
| WO2013114164A1 (en) * | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Method for obtaining glycoprotein composition with increased afucosylation content |
| US10059770B2 (en) | 2012-01-30 | 2018-08-28 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of a glycoprotein composition |
| WO2013138159A1 (en) | 2012-03-15 | 2013-09-19 | Amgen Inc. | Methods of determining exposure to uv light |
| US10481164B2 (en) | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
| JP6273205B2 (ja) * | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| US9677105B2 (en) | 2013-03-14 | 2017-06-13 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| WO2015011660A1 (en) | 2013-07-23 | 2015-01-29 | Biocon Limited | Methods for controlling fucosylation levels in proteins |
| LT3110961T (lt) * | 2014-02-27 | 2020-02-10 | F. Hoffmann-La Roche Ag | Ląstelių augimo ir glikozilinimo moduliavimas, gaminant rekombinantinį glikoproteiną |
| EP3215604A4 (en) * | 2014-10-27 | 2018-07-25 | Agency For Science, Technology And Research | Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity |
| KR102623965B1 (ko) | 2014-12-01 | 2024-01-11 | 암젠 인크 | 당단백질의 글리칸 함량 수준을 조작하는 방법 |
-
2015
- 2015-12-01 KR KR1020177016893A patent/KR102623965B1/ko active Active
- 2015-12-01 EA EA202091598A patent/EA202091598A3/ru unknown
- 2015-12-01 CN CN201580071982.6A patent/CN107109455B/zh active Active
- 2015-12-01 WO PCT/US2015/063271 patent/WO2016089919A1/en not_active Ceased
- 2015-12-01 IL IL276165A patent/IL276165B/en unknown
- 2015-12-01 AU AU2015355087A patent/AU2015355087C1/en active Active
- 2015-12-01 SG SG11201704351WA patent/SG11201704351WA/en unknown
- 2015-12-01 PL PL15816598T patent/PL3227454T3/pl unknown
- 2015-12-01 SG SG10202002458PA patent/SG10202002458PA/en unknown
- 2015-12-01 MX MX2017006997A patent/MX385409B/es unknown
- 2015-12-01 DK DK15816598.5T patent/DK3227454T3/da active
- 2015-12-01 ES ES15816598T patent/ES2784503T3/es active Active
- 2015-12-01 PT PT158165985T patent/PT3227454T/pt unknown
- 2015-12-01 EA EA201791223A patent/EA036178B1/ru not_active IP Right Cessation
- 2015-12-01 EP EP15816598.5A patent/EP3227454B1/en not_active Revoked
- 2015-12-01 HU HUE15816598A patent/HUE049201T2/hu unknown
- 2015-12-01 SI SI201531140T patent/SI3227454T1/sl unknown
- 2015-12-01 JP JP2017547931A patent/JP6698681B2/ja active Active
- 2015-12-01 EP EP20154019.2A patent/EP3680344A1/en active Pending
- 2015-12-01 US US15/529,950 patent/US10167492B2/en active Active
- 2015-12-01 CA CA2969225A patent/CA2969225C/en active Active
- 2015-12-01 LT LTEP15816598.5T patent/LT3227454T/lt unknown
-
2017
- 2017-05-29 CL CL2017001369A patent/CL2017001369A1/es unknown
- 2017-05-29 IL IL252569A patent/IL252569B/en active IP Right Grant
- 2017-05-31 ZA ZA2017/03729A patent/ZA201703729B/en unknown
-
2018
- 2018-11-14 US US16/191,352 patent/US20190085370A1/en not_active Abandoned
-
2020
- 2020-02-05 US US16/783,117 patent/US10822630B2/en active Active
- 2020-03-31 AU AU2020202302A patent/AU2020202302A1/en not_active Abandoned
- 2020-04-07 CY CY20201100325T patent/CY1123247T1/el unknown
- 2020-04-30 JP JP2020080270A patent/JP7066775B2/ja active Active
- 2020-09-29 ZA ZA2020/06002A patent/ZA202006002B/en unknown
- 2020-10-02 US US17/062,199 patent/US20210017565A1/en not_active Abandoned
-
2022
- 2022-01-28 AU AU2022200586A patent/AU2022200586A1/en not_active Abandoned
- 2022-04-26 JP JP2022072126A patent/JP2022101669A/ja active Pending
-
2023
- 2023-01-18 US US18/156,025 patent/US20230159974A1/en not_active Abandoned
-
2024
- 2024-04-10 JP JP2024063188A patent/JP2024095777A/ja active Pending
- 2024-06-24 AU AU2024204313A patent/AU2024204313A1/en not_active Abandoned
-
2025
- 2025-09-01 AU AU2025223948A patent/AU2025223948A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE049201T2 (hu) | Eljárás glikoprotein glikántartalmának befolyásolására | |
| PL3848163T3 (pl) | Zespół pojemników | |
| IL249981A0 (en) | Method | |
| LT3126395T (lt) | Daugiaspecifiniai antikūnai | |
| FI20145442A7 (fi) | Menetelmä kartongin valmistamiseksi | |
| FI20146127A7 (fi) | Prosessi hiilivetyjen valmistamiseksi | |
| DK3341479T3 (da) | LNA-G-Proces | |
| HUE057118T2 (hu) | Folyamat | |
| FI20155728A7 (fi) | Menetelmä kiinteän ligniinin valmistamiseksi | |
| EP4067461C0 (en) | HIGH EFFICIENCY POUR POINT REDUCTION PROCESS | |
| HUE048056T2 (hu) | Eljárás a guayul izoprén alkotóelemeinek elválasztására | |
| DK3102275T3 (da) | Nasal dilatator | |
| FI20145326A7 (fi) | Menetelmä nosturin kääntöajamiseksi | |
| FI20146005A7 (fi) | Menetelmä massan valmistamiseksi. | |
| FI11110U1 (fi) | Separointilaitteisto | |
| TH1601002609A (th) | กระบวนการทำอะดามันทานาไมด์ | |
| UA31307S (uk) | Малюнок для упаковки | |
| UA31305S (uk) | Малюнок для упаковки | |
| UA32002S (uk) | Опаковання для закваски | |
| UA32001S (uk) | Опаковання для закваски | |
| TH1701000091A (th) | วิธีการสำหรับการยึดติดผ้า-อิลาสโตเมอร์ | |
| TH1601001263A (th) | อิมัลชันและวิธีการผลิตสำหรับสิ่งนั้น | |
| UA31412S (uk) | Малюнок для упаковки | |
| TH1601002892A (th) | วิธีการสำหรับการเพิ่มความแข็งแรงของกระดาษ | |
| UA31554S (uk) | Опаковання для закваски |